BioMarin Pharmaceutical Inc.

DB:BM8 Stock Report

Market Cap: €12.2b

BioMarin Pharmaceutical Past Earnings Performance

Past criteria checks 5/6

BioMarin Pharmaceutical's earnings have been declining at an average annual rate of -11.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 9% per year. BioMarin Pharmaceutical's return on equity is 6%, and it has net margins of 11.7%.

Key information

-11.3%

Earnings growth rate

-12.3%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate9.0%
Return on equity6.0%
Net Margin11.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How BioMarin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:BM8 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,7533221,03333
30 Jun 242,5882579950
31 Mar 242,4722059380
31 Dec 232,4191689230
30 Sep 232,311147856541
30 Jun 232,2351008570
31 Mar 232,173728470
31 Dec 222,0961428310
30 Sep 222,008848260
30 Jun 221,912547920
31 Mar 221,880397800
31 Dec 211,846-647590
30 Sep 211,849167370
30 Jun 211,9178377330
31 Mar 211,8447957250
31 Dec 201,8608547380
30 Sep 201,8638527300
30 Jun 201,8471227210
31 Mar 201,8051147060
31 Dec 191,704-246810
30 Sep 191,603-436570
30 Jun 191,533-1106360
31 Mar 191,519-906280
31 Dec 181,491-776040
30 Sep 181,496-1256000
30 Jun 181,439-1255820
31 Mar 181,383-1455730
31 Dec 171,314-1175540
30 Sep 171,255-1565370
30 Jun 171,201-1815250
31 Mar 171,184-5634910
31 Dec 161,117-6304770
30 Sep 161,045-4714410
30 Jun 16974-5244160
31 Mar 16924-1874080
31 Dec 15890-1724020
30 Sep 15892-3103850
30 Jun 15859-2123660
31 Mar 15801-1633320
31 Dec 14749-1342990
30 Sep 14666-1262740
30 Jun 14627-1872620
31 Mar 14572-1752440
31 Dec 13548-1762350

Quality Earnings: BM8 has high quality earnings.

Growing Profit Margin: BM8's current net profit margins (11.7%) are higher than last year (6.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BM8 has become profitable over the past 5 years, growing earnings by -11.3% per year.

Accelerating Growth: BM8's earnings growth over the past year (119.2%) exceeds its 5-year average (-11.3% per year).

Earnings vs Industry: BM8 earnings growth over the past year (119.2%) exceeded the Biotechs industry -18.2%.

Return on Equity

High ROE: BM8's Return on Equity (6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 04:29
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioMarin Pharmaceutical Inc. is covered by 56 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Ishan MajumdarBaptista Research
Huidong WangBarclays